Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
CLNN Stock Summary
In the News
3 Penny Stocks That Could Be Multibaggers in the Making: March Edition
When it comes to deciding whether you should acquire penny stocks or not, the answer is no. Okay, so we're done here, right?
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to loss of $0.16 per share a year ago.
7 Underappreciated Penny Stocks That Pack a Wallop
Let's be brutally honest with each other – underappreciated penny stocks are that way for a reason. I'm not going to say they stink but they're incredibly unpredictable.
Clene to Present at Cantor Fitzgerald Annual Global Healthcare Conference
SALT LAKE CITY, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis, today announced that it will participate in the Cantor Fitzgerald Annual Global Healthcare Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will be participating in the presentation and 1x1 investor meetings.
Clene to Present at Upcoming September Conferences
SALT LAKE CITY, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson's disease, and multiple sclerosis, today announced that it will participate in the following investor conferences in September.
Clene to Present at the Canaccord Genuity 43rd Annual Growth Conference
SALT LAKE CITY, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, today announced that it will present at the Canaccord Genuity 43rd Annual Growth Conference. Rob Etherington, Chief Executive Officer, and Morgan Brown, Chief Financial Officer, will participate in the presentation and investor meetings.
10 Top Penny Stocks To Watch Right Now For Under $1
Welcome to the world of penny stocks. This is a corner of the stock market that piques interest and raises eyebrows in equal measure.
Clene Inc. (CLNN) Reports Q1 Loss, Misses Revenue Estimates
Clene Inc. (CLNN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.21 per share a year ago.
Clene Inc. (CLNN) Reports Q4 Loss, Tops Revenue Estimates
Clene Inc. (CLNN) delivered earnings and revenue surprises of -6.67% and 73.33%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Webcast set for 7:30 a.m. ET on March 9 Webcast set for 7:30 a.m. ET on March 9
CLNN Financial details
CLNN Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net income per share | -0.94 | -1.1 | -0.16 | -0.23 | -0.47 | |
Operating cash flow per share | -0.76 | -1.08 | -0.56 | -0.6 | -0.29 | |
Free cash flow per share | -0.78 | -1.1 | -0.58 | -0.68 | -0.29 | |
Cash per share | 0.51 | 3.39 | 0.82 | 0.36 | 0.33 | |
Book value per share | -3.9 | 0.02 | 0.2 | 0.05 | 0.13 | |
Tangible book value per share | -3.9 | 0.02 | 0.2 | 0.05 | 0.13 | |
Share holders equity per share | -3.9 | 0.02 | 0.2 | 0.05 | 0.13 | |
Interest debt per share | 0.17 | 0.3 | 0.4 | 0.54 | 0.3 | |
Market cap | 181.91M | 189.39M | 252.39M | 65.2M | 31.12M | |
Enterprise value | 176M | 134.44M | 226.14M | 78.7M | 34.46M | |
P/E ratio | -11.18 | -9.82 | -25.91 | -4.27 | -0.63 | |
Price to sales ratio | 0 | 919.38 | 349.09 | 137.85 | 47.59 | |
POCF ratio | -13.78 | -10.01 | -7.29 | -1.67 | -1.03 | |
PFCF ratio | -13.48 | -9.8 | -7.02 | -1.48 | -1.02 | |
P/B Ratio | -2.68 | 555.41 | 20.04 | 20.14 | 2.32 | |
PTB ratio | -2.68 | 555.41 | 20.04 | 20.14 | 2.32 | |
EV to sales | 0 | 652.63 | 312.79 | 166.38 | 52.7 | |
Enterprise value over EBITDA | -11.85 | -8.4 | -4.76 | -1.75 | -0.89 | |
EV to operating cash flow | -13.34 | -7.1 | -6.53 | -2.02 | -1.14 | |
EV to free cash flow | -13.05 | -6.96 | -6.29 | -1.78 | -1.13 | |
Earnings yield | -0.09 | -0.1 | -0.04 | -0.23 | -1.59 | |
Free cash flow yield | -0.07 | -0.1 | -0.14 | -0.68 | -0.98 | |
Debt to equity | -0.04 | 12.68 | 1.91 | 9.83 | 2.04 | |
Debt to assets | 0.19 | 0.06 | 0.38 | 0.72 | 0.52 | |
Net debt to EBITDA | 0.4 | 3.43 | 0.55 | -0.3 | -0.09 | |
Current ratio | 2.2 | 5.4 | 9.06 | 2.11 | 1.53 | |
Interest coverage | -185.59 | -17.9 | -52.04 | -13.75 | -8.89 | |
Income quality | 0.82 | 0.98 | 3.55 | 1.3 | 0.61 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 25 | 26.02 | 35.81 | 20.03 | |
Research and developement to revenue | 0 | 73.81 | 39.3 | 67.48 | 38.56 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.02 | 0.02 | 0.04 | 0.13 | 0.01 | |
Capex to revenue | 0 | -1.88 | -1.84 | -10.95 | -0.5 | |
Capex to depreciation | -0.35 | -0.4 | -1.39 | -5.08 | -0.19 | |
Stock based compensation to revenue | 0 | 3.69 | 17.13 | 18 | 13.94 | |
Graham number | 9.07 | 0.69 | 0.85 | 0.51 | 1.16 | |
ROIC | 0.26 | -2.47 | -1.04 | -0.56 | -0.89 | |
Return on tangible assets | -1.09 | -0.28 | -0.15 | -0.34 | -0.95 | |
Graham Net | -4.23 | -0.39 | 0.02 | -0.27 | -0.03 | |
Working capital | 5.16M | 51.32M | 48.56M | 15.34M | 13.52M | |
Tangible asset value | -67.77M | 341K | 12.6M | 3.24M | 13.39M | |
Net current asset value | -73.17M | -4.91M | 4.12M | -12.06M | -99K | |
Invested capital | -0.04 | 12.68 | 1.91 | 9.83 | 2.04 | |
Average receivables | 0 | 1.39M | 1.89M | 901K | 763.5K | |
Average payables | 0 | 1.01M | 1.52M | 2.47M | 2.26M | |
Average inventory | 0 | 109.5K | 116K | 42K | 40K | |
Days sales outstanding | 0 | 3.84K | 814.31 | 145.85 | 746.74 | |
Days payables outstanding | 360.54 | 6.31K | 2.43K | 42.31K | 300.64 | |
Days of inventory on hand | 11.36 | 1.07K | 51.78 | 603.65 | 7.4 | |
Receivables turnover | 0 | 0.09 | 0.45 | 2.5 | 0.49 | |
Payables turnover | 1.01 | 0.06 | 0.15 | 0.01 | 1.21 | |
Inventory turnover | 32.14 | 0.34 | 7.05 | 0.6 | 49.35 | |
ROE | 0.24 | -56.53 | -0.77 | -4.72 | -3.7 | |
Capex per share | -0.02 | -0.02 | -0.02 | -0.08 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0 | 0 | |
Net income per share | 0.13 | -0.18 | -0.29 | -0.02 | -0.08 | |
Operating cash flow per share | -0.12 | -0.12 | -0.08 | -0.05 | -0.06 | |
Free cash flow per share | -0.14 | -0.12 | -0.08 | -0.05 | -0.06 | |
Cash per share | 0.36 | 0.24 | 0.57 | 0.33 | 0.27 | |
Book value per share | 0.05 | -0.02 | 0.25 | 0.17 | 0.1 | |
Tangible book value per share | 0.05 | -0.02 | 0.25 | 0.17 | 0.1 | |
Share holders equity per share | 0.05 | -0.02 | 0.25 | 0.17 | 0.1 | |
Interest debt per share | 0.5 | 0.44 | 0.38 | 0.24 | 0.22 | |
Market cap | 65.2M | 85.94M | 75.72M | 63.68M | 38.09M | |
Enterprise value | 78.7M | 99.85M | 58.15M | 53.48M | 41.43M | |
P/E ratio | 1.89 | -1.55 | -0.75 | -6.58 | -0.94 | |
Price to sales ratio | 278.65 | 803.14 | 281.5 | 589.6 | 224.06 | |
POCF ratio | -8.45 | -9.32 | -10.79 | -9.42 | -5.28 | |
PFCF ratio | -6.92 | -9.05 | -10.85 | -9.35 | -5.25 | |
P/B Ratio | 20.14 | -52.82 | 3.52 | 2.97 | 2.84 | |
PTB ratio | 20.14 | -52.82 | 3.52 | 2.97 | 2.84 | |
EV to sales | 336.31 | 933.19 | 216.16 | 495.17 | 243.71 | |
Enterprise value over EBITDA | -7.71 | -9.75 | -2.4 | -5.6 | -4.36 | |
EV to operating cash flow | -10.2 | -10.83 | -8.28 | -7.91 | -5.74 | |
EV to free cash flow | -8.36 | -10.52 | -8.33 | -7.86 | -5.71 | |
Earnings yield | 0.13 | -0.16 | -0.33 | -0.04 | -0.27 | |
Free cash flow yield | -0.14 | -0.11 | -0.09 | -0.11 | -0.19 | |
Debt to equity | 9.83 | -19.89 | 1.47 | 1.49 | 2.04 | |
Debt to assets | 0.72 | 0.81 | 0.47 | 0.53 | 0.52 | |
Net debt to EBITDA | -1.32 | -1.36 | 0.73 | 1.07 | -0.35 | |
Current ratio | 2.11 | 1.47 | 9.31 | 3.04 | 1.53 | |
Interest coverage | -11.84 | -9.53 | -9.36 | 8.03 | -8.28 | |
Income quality | 7.32 | 0.78 | 0.28 | 2.8 | 0.71 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | -0.08 | 0 | |
Sales general and administrative to revenue | 18.19 | 29.72 | 12.88 | 33.94 | 19.29 | |
Research and developement to revenue | 33.21 | 69.11 | 24.59 | 55.3 | 37.16 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0.22 | 0.03 | -0.01 | 0.01 | 0.01 | |
Capex to revenue | -7.27 | -2.6 | 0.14 | -0.44 | -0.26 | |
Capex to depreciation | -5.6 | -0.69 | 0.09 | -0.11 | -0.1 | |
Stock based compensation to revenue | 8.67 | 20.78 | 9.11 | 22.19 | 12.04 | |
Graham number | 0.38 | 0.3 | 1.28 | 0.27 | 0.43 | |
ROIC | 2.13 | -0.33 | -0.08 | -0.13 | -0.22 | |
Return on tangible assets | 0.19 | -0.35 | -0.37 | -0.04 | -0.19 | |
Graham Net | -0.24 | -0.27 | 0.04 | 0.03 | -0.02 | |
Working capital | 15.34M | 7.95M | 47.64M | 31.18M | 13.52M | |
Tangible asset value | 3.24M | -1.63M | 21.53M | 21.41M | 13.39M | |
Net current asset value | -12.06M | -16.69M | 7.06M | 7.42M | -99K | |
Invested capital | 9.83 | -19.89 | 1.47 | 1.49 | 2.04 | |
Average receivables | 2.35M | 3.04M | 2.07M | 1.08M | 1.24M | |
Average payables | 3.23M | 1.81M | 727K | 1.37M | 1.7M | |
Average inventory | 40.5K | 65.5K | 70K | 78K | 70.5K | |
Days sales outstanding | 1.14K | 2.62K | 340.93 | 956.67 | 708.35 | |
Days payables outstanding | 38.75K | 10.94K | 1.15K | 14.17K | 294.26 | |
Days of inventory on hand | 552.86 | 1.58K | 70.91 | 780 | 7.24 | |
Receivables turnover | 0.08 | 0.03 | 0.26 | 0.09 | 0.13 | |
Payables turnover | 0 | 0.01 | 0.08 | 0.01 | 0.31 | |
Inventory turnover | 0.16 | 0.06 | 1.27 | 0.12 | 12.43 | |
ROE | 2.66 | 8.53 | -1.17 | -0.11 | -0.76 | |
Capex per share | -0.03 | 0 | 0 | 0 | 0 |
CLNN Frequently Asked Questions
What is Clene Inc. stock symbol ?
Clene Inc. is a US stock , located in Salt lake city of Ut and trading under the symbol CLNN
Is Clene Inc. buy or a sell ?
1 stock analysts have 1 predictions with a medium analyst target price of $10. The lowest prediction is $10 and the highest is $10
What is CLNN stock prediction ?
What is Clene Inc. stock quote today ?
Clene Inc. stock price is $0.427 today.
Is Clene Inc. stock public?
Yes, Clene Inc. is a publicly traded company.